Avances en Medicina
Idarucizumab y dabigatrán. Datos del estudio RE-VERSE AD
Idarucizumab and dabigatran. Data from the RE-VERSE AD study
Leído
15529
Vecesse ha leído el artículo
1821
Total PDF
13708
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 53 | 5 | 58 |
| 2025 11 | 223 | 17 | 240 |
| 2025 10 | 208 | 10 | 218 |
| 2025 9 | 169 | 15 | 184 |
| 2025 8 | 176 | 20 | 196 |
| 2025 7 | 197 | 11 | 208 |
| 2025 6 | 300 | 7 | 307 |
| 2025 5 | 162 | 8 | 170 |
| 2025 4 | 206 | 5 | 211 |
| 2025 3 | 168 | 8 | 176 |
| 2025 2 | 148 | 10 | 158 |
| 2025 1 | 105 | 9 | 114 |
| 2024 12 | 186 | 5 | 191 |
| 2024 11 | 275 | 6 | 281 |
| 2024 10 | 419 | 13 | 432 |
| 2024 9 | 401 | 21 | 422 |
| 2024 8 | 269 | 16 | 285 |
| 2024 7 | 305 | 8 | 313 |
| 2024 6 | 213 | 8 | 221 |
| 2024 5 | 278 | 10 | 288 |
| 2024 4 | 219 | 20 | 239 |
| 2024 3 | 217 | 11 | 228 |
| 2024 2 | 198 | 8 | 206 |
| 2024 1 | 326 | 6 | 332 |
| 2023 12 | 204 | 10 | 214 |
| 2023 11 | 251 | 10 | 261 |
| 2023 10 | 391 | 9 | 400 |
| 2023 9 | 243 | 5 | 248 |
| 2023 8 | 171 | 5 | 176 |
| 2023 7 | 212 | 4 | 216 |
| 2023 6 | 172 | 4 | 176 |
| 2023 5 | 194 | 11 | 205 |
| 2023 4 | 188 | 9 | 197 |
| 2023 3 | 200 | 22 | 222 |
| 2023 2 | 172 | 22 | 194 |
| 2022 1 | 137 | 9 | 146 |
| 2022 12 | 105 | 10 | 115 |
| 2022 11 | 164 | 19 | 183 |
| 2022 10 | 148 | 17 | 165 |
| 2022 9 | 141 | 37 | 178 |
| 2022 8 | 107 | 20 | 127 |
| 2022 7 | 65 | 10 | 75 |
| 2022 6 | 95 | 23 | 118 |
| 2022 5 | 109 | 18 | 127 |
| 2022 4 | 88 | 13 | 101 |
| 2022 3 | 100 | 21 | 121 |
| 2022 2 | 105 | 12 | 117 |
| 2021 1 | 116 | 16 | 132 |
| 2021 12 | 91 | 18 | 109 |
| 2021 11 | 100 | 21 | 121 |
| 2021 10 | 88 | 27 | 115 |
| 2021 9 | 70 | 29 | 99 |
| 2021 8 | 78 | 11 | 89 |
| 2021 7 | 67 | 19 | 86 |
| 2021 6 | 57 | 26 | 83 |
| 2021 5 | 64 | 28 | 92 |
| 2021 4 | 178 | 48 | 226 |
| 2021 3 | 81 | 27 | 108 |
| 2021 2 | 43 | 11 | 54 |
| 2020 1 | 62 | 16 | 78 |
| 2020 12 | 51 | 15 | 66 |
| 2020 11 | 57 | 15 | 72 |
| 2020 10 | 49 | 10 | 59 |
| 2020 9 | 48 | 20 | 68 |
| 2020 8 | 79 | 14 | 93 |
| 2020 7 | 57 | 15 | 72 |
| 2020 6 | 58 | 15 | 73 |
| 2020 5 | 63 | 18 | 81 |
| 2020 4 | 72 | 10 | 82 |
| 2020 3 | 76 | 20 | 96 |
| 2020 2 | 100 | 8 | 108 |
| 2020 1 | 112 | 24 | 136 |
| 2019 12 | 96 | 16 | 112 |
| 2019 11 | 41 | 9 | 50 |
| 2019 10 | 70 | 6 | 76 |
| 2019 9 | 92 | 13 | 105 |
| 2019 8 | 69 | 15 | 84 |
| 2019 7 | 105 | 13 | 118 |
| 2019 6 | 159 | 53 | 212 |
| 2019 5 | 288 | 104 | 392 |
| 2019 4 | 165 | 51 | 216 |
| 2019 3 | 52 | 13 | 65 |
| 2019 2 | 49 | 15 | 64 |
| 2019 1 | 46 | 18 | 64 |
| 2018 12 | 53 | 20 | 73 |
| 2018 11 | 86 | 23 | 109 |
| 2018 10 | 194 | 9 | 203 |
| 2018 9 | 92 | 27 | 119 |
| 2018 8 | 38 | 14 | 52 |
| 2018 7 | 28 | 8 | 36 |
| 2018 6 | 46 | 8 | 54 |
| 2018 5 | 46 | 12 | 58 |
| 2018 4 | 39 | 9 | 48 |
| 2018 3 | 33 | 5 | 38 |
| 2018 2 | 12 | 5 | 17 |
| 2018 1 | 16 | 3 | 19 |
| 2017 12 | 7 | 4 | 11 |
| 2017 11 | 29 | 8 | 37 |
| 2017 10 | 19 | 15 | 34 |
| 2017 9 | 12 | 10 | 22 |
| 2017 8 | 30 | 3 | 33 |
| 2017 7 | 34 | 30 | 64 |
| 2017 6 | 33 | 25 | 58 |
| 2017 5 | 25 | 21 | 46 |
| 2017 4 | 22 | 15 | 37 |
| 2017 3 | 26 | 29 | 55 |
| 2017 2 | 28 | 14 | 42 |
| 2016 1 | 24 | 17 | 41 |
| 2016 12 | 32 | 17 | 49 |
| 2016 11 | 202 | 9 | 211 |
| 2016 10 | 44 | 18 | 62 |
| 2016 9 | 37 | 16 | 53 |
| 2016 8 | 49 | 21 | 70 |
| 2016 7 | 40 | 22 | 62 |
Mostrar todo
